The Phase Ib, open-label single-arm study will enroll up to approximately 30 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) at multiple cancer centers in the US. Patients will receive escalating doses of SGN-40 in combination with Rituxan and Gemzar. The study will assess safety, pharmacokinetics and preliminary antitumor activity of the combination regimen.
Thomas Reynolds, chief medical officer of Seattle Genetics, said: “The SGN-40 plus Rituxan and Gemzar combination trial complements our other ongoing DLBCL trials, including a Phase IIb trial evaluating SGN-40 in combination with Rituxan plus chemotherapy in the second-line setting and a single-agent Phase II trial in relapsed or refractory patients.”